Open AccessTILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals
Author(s) -
Brian Angus,
Fiona Lampe,
Giuseppe Tambussi,
Claudine Duvivier,
Christine Katlama,
Mike Youle,
Ian Williams,
Bonaventura Clotet,
Martin Fisher,
Frank A. Post,
Abdel Babiker,
Andrew Phillips
Publication year - 2008
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3282f511f1
Subject(s) - medicine , toxicity , antiretroviral therapy , randomized controlled trial , surgery , human immunodeficiency virus (hiv) , viral load , immunology
We aimed to see if structured treatment interruption (STI) could be supported safely with the use of two cycles of IL-2 (4.5 MIU q12h subcutaneously 5 days) before STI to prolong the time before therapy restarted.